ERLEADA®(apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with: • Metastatic castration-sensitive prostate cancer (mCSPC) • Non-metastatic castration-resistant prostate cancer (nmCRPC) Please see Important Safety Information on page 16 and full Prescribing Information for ERLEADA®.
Full Answer
How long should I take Erleada for prostate cancer?
Jan 31, 2020 · Erleada (apalutamide) is an oral therapy developed by Janssen Pharmaceuticals to treat some types of prostate cancer. The therapy is approved in the U.S. and Europe to treat metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT), and to treat non-metastatic castration-resistant prostate ...
What is Erleada®?
Sep 09, 2021 · Official Answer. Erleada (apalutamide) is used for the treatment of metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer. Metastatic castration-sensitive prostate cancer (mCSPC) refers to prostate cancer that still responds to androgen deprivation therapy (ADT) and has spread to other parts of ...
What is Erleada (apalutamide) used for?
Oct 14, 2020 · Erleada (apalutamide) is a prescription medication used to treat prostate cancer that has spread to other parts of the body and still responds to a medical or surgical treatment that lowers testosterone, or that has not spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone.
Does Erleada work for mhspc?
Jun 03, 2021 · Erleada (apalutamide) has already been FDA-approved for use in non-metastatic castration-resistant prostate cancer (non-m CRPC), which affects relatively few men (remembering that metastatic was defined by bone scan/CT rather than PET scan). Now we have evidence that it increases overall survival in men with metastatic hormone-sensitive prostate …
Does Erleada cure prostate cancer?
Erleada prolongs survival in non-metastatic Castration-resistant Prostate Cancer and for those with metastatic disease. Erleada prolongs survival in non-metastatic Castration-resistant Prostate Cancer and for those with metastatic disease.Feb 17, 2021
Is Erleada for metastatic prostate cancer?
Erleada for metastatic castration-sensitive prostate cancer Erleada is FDA-approved to treat metastatic castration-sensitive prostate cancer (mCSPC). Metastatic prostate cancer is cancer that has spread to other parts of your body.
How long can a person take Erleada?
Erleada (apalutamide) is usually taken until cancer progresses past a certain point or you start to have unacceptable side effects. In the SPARTAN clinical trial (NCT01946204) using apalutamide for men with castration-resistant metastasis-free prostate cancer, some patients were still using apalutamide at 36 months.Apr 27, 2021
What is the best treatment for prostate cancer that has spread?
If your cancer has spread beyond your prostate to other areas of your body, your doctor may recommend: Chemotherapy. Chemotherapy can slow the growth of cancer cells, relieve signs and symptoms of cancer, and prolong the lives of men with advanced prostate cancer.May 8, 2020
What are the side effects of Erleada?
Common side effects of Erleada include:fatigue,high blood pressure (hypertension),rash,diarrhea,nausea,weight loss,joint pain,falls,More items...
When is the best time to take Erleada?
Take your prescribed dose of ERLEADA® 1 time a day, at the same time each day. Take ERLEADA® with or without food. Swallow ERLEADA® tablets whole. If you miss a dose of ERLEADA®, take your normal dose as soon as possible on the same day.
Does Erleada raise blood pressure?
This medication can cause high blood pressure (hypertension). Patients should have their blood pressure checked regularly during therapy. Any hypertension should be treated appropriately. If hypertension cannot be controlled, the medication may be stopped.
Does Erleada cause shortness of breath?
chest pain or discomfort at rest or with activity. shortness of breath. numbness or weakness of the face, arm, or leg, especially on one side of the body.
What class of drug is Erleada?
This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.
What is the life expectancy when prostate cancer spreads to bones?
How is survival affected?Advanced prostate cancerOne-year survivalFive-year survivalwithout bone metastasis87 percent56 percentwith bone metastasis47 percent3 percentwith bone metastasis and skeletal-related events40 percentless than 1 percent
How do you know if prostate cancer has spread to bones?
Symptoms. Bone pain is often the first sign that prostate cancer has spread to bones. Pain is caused by changes to the structure of the bones and inflammation from cancer cells. It may feel like a sharp pain or dull ache.Mar 9, 2021
How long can you live when prostate cancer spreads to bones?
There is currently no cure for advanced prostate cancer, but advances in treatments are extending life expectancy and improving quality of life. The ACS state that the 5-year relative survival rate for individuals with prostate cancer that has spread to distant lymph nodes, organs, or the bones is 29 percent .
What is apalutamide?
Erleada (Apalutamide) Erleada (apalutamide) is an oral therapy developed by Janssen Pharmaceuticals to treat some types of prostate cancer. The therapy is approved in the U.S. and Europe to treat metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy ...
Does androgen cause prostate cancer?
In cancer, androgen signaling promotes cancer growth. The first line of treatment for prostate cancer is usually ADT. However, nearly all patients progress to a more aggressive, castration-resistant cancer type, which has abnormal androgen-receptor signaling. This is because the cancerous cells are producing more of the androgen receptor ...
What is the role of androgens in the development of the prostate?
The prostate is a small gland in the groin that is important for the production of seminal fluid. Androgens are male sex hormones that play a critical role in the development and function of the prostate. In cancer, androgen signaling promotes cancer growth. The first line of treatment for prostate cancer is usually ADT.
What is Erleada used for?
Erleada (apalutamide) is used for the treatment of metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer. Metastatic castration-sensitive prostate cancer (mCSPC) refers to prostate cancer that still responds to androgen deprivation therapy (ADT) and has spread to other parts of the body.
What is NM-CRPC?
Non-metastatic castration-resistant prostate cancer (NM-CRPC) refers to prostate cancer that no longer responds to androgen deprivation therapy (ADT) or surgical treatments that lower testosterone, but has not yet been discovered in other parts of the body. Erleada is an androgen receptor inhibitor. It works by blocking the effect of androgens on ...
Subscribe to MedicineNet's Cancer Report Newsletter
By clicking "Submit," I agree to the MedicineNet Terms and Conditions and Privacy Policy. I also agree to receive emails from MedicineNet and I understand that I may opt out of MedicineNet subscriptions at any time.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Saturday, December 7, 2019
In a retrospective study presented at the Society for Urologic Oncology meeting, researchers at the Mayo Clinic reported on 112 patients with metastatic castration-resistant prostate cancer (mCRPC).
Thursday, May 16, 2019
Erleada (apalutamide) has already been FDA-approved for use in non-metastatic castration-resistant prostate cancer (non-m CRPC), which affects relatively few men (remembering that metastatic was defined by bone scan/CT rather than PET scan).
Tuesday, June 6, 2017
In the US, only 3% of new patients are newly diagnosed with metastatic, hormone-sensitive prostate cancer (mHSPC). "Metastatic," for the purposes of this analysis only includes distant metastases (Stage M1), but not pelvic lymph node metastases (Stage N1).
